Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs
- PMID: 34135088
- DOI: 10.1124/dmd.121.000409
Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs
Abstract
Inconsistencies in pharmacokinetic parameters between individual animals in preclinical studies are a common occurrence. Often such differences between animals are simply accepted as experimental variability rather than as indications of specific differences in animal phenotype that could lead to a different interpretation of the data. The fraction unbound in plasma is one factor influencing pharmacokinetic parameters and is typically determined using pooled plasma from multiple animals, making the assumption that there is limited population variance. However, this assumption is not often tested and may not hold true if there are polymorphisms affecting binding or variation in the concentrations of individual plasma proteins that could give rise to different fraction unbound phenotypes in individual animals. During profiling of a novel Syk inhibitor, AZ8399, striking interindividual differences in total plasma clearance and volume of distribution were observed between dogs consistent with differences in fraction unbound between animals. Determination of the fraction unbound showed a ∼5-fold difference in fraction unbound between the animals in the study. Broader analysis of individual dogs across a colony demonstrated a correlation between individual animal fraction unbound with total plasma clearance and volume of distribution. The concentrations of the common drug-binding proteins albumin and α1-acid glycoprotein in plasma were determined, and α1-acid glycoprotein levels were found to correlate with fraction unbound. Finally, single-nucleotide polymorphisms were identified at c.502 and c.522 of exon 5 of the dog α1-acid glycoprotein gene that may be correlated to the α1-acid glycoprotein concentration phenotype observed. SIGNIFICANCE STATEMENT: The current work demonstrates the potential for significant interindividual differences in plasma fraction unbound in beagle dogs and goes on to examine the underlying cause for the compound described. The findings suggest that the application of a population mean value of fraction unbound generated from a pooled sample may not always be appropriate and could introduce significant errors in scaling of in vitro clearance values, PBPK understanding, and interpretation of PKPD or toxicokinetic data in the context of unbound concentrations.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.
Similar articles
-
Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.Clin Cancer Res. 2012 Apr 1;18(7):2066-79. doi: 10.1158/1078-0432.CCR-11-2684. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351688 Free PMC article. Clinical Trial.
-
Canine orosomucoid (alpha-1 acid glycoprotein) variants and their influence on drug plasma protein binding.J Vet Pharmacol Ther. 2021 Jan;44(1):116-125. doi: 10.1111/jvp.12899. Epub 2020 Aug 3. J Vet Pharmacol Ther. 2021. PMID: 32744755 Free PMC article.
-
Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.Anticancer Res. 2014 May;34(5):2283-9. Anticancer Res. 2014. PMID: 24778032
-
Protein binding in antiretroviral therapies.AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. doi: 10.1089/088922203769232629. AIDS Res Hum Retroviruses. 2003. PMID: 14585213 Review.
-
Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein.Pharm Res. 2018 Dec 28;36(2):30. doi: 10.1007/s11095-018-2551-x. Pharm Res. 2018. PMID: 30593605 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous